#1 Clinical Trials Search in Europe

Xp-Dc+Tl+Klh

Clinical trials are investigating Xp-Dc+Tl+Klh in women with epithelial ovarian cancer. The studies are looking at whether this treatment can trigger an immune response and help during neoadjuvant or adjuvant chemotherapy. They also assess early safety and biological activity in small patient groups.

Table of contents

Trial overview

The clinical trial in the source data studied Xp-Dc+Tl+Klh in women with epithelial ovarian cancer.[1] The study was called the NEODOC study and was designed to test whether tumor-lysate loaded XP-DC could improve the immune response in patients receiving chemotherapy.[1]

This was an interventional study, which means the research team gave a study treatment and then measured the results.[1] The study was completed and enrolled 10 participants.[1]

Who was studied

The trial focused on patients with epithelial ovarian cancer, a type of ovarian cancer that starts in the cells covering the ovary.[1] The study description shows that the target group was patients treated with neoadjuvant chemotherapy or (neo-)adjuvant chemotherapy.[1]

Neoadjuvant chemotherapy means treatment given before the main cancer treatment, and adjuvant chemotherapy means treatment given after the main treatment to help lower the chance of cancer returning.[1] The trial therefore looked at a fairly specific patient group rather than a broad cancer population.[1]

Study design and phase

The study was a Phase 1/2 trial.[1] Early-phase trials like this are usually done to look for signs of safety and early activity, before larger studies are planned.[1]

The intervention was listed as Drug: XP-DC+TL+KLH (INTRANODAL).[1] The source data also says the study used tumor-lysate loaded XP-DC in epithelial ovarian cancer patients undergoing chemotherapy.[1]

What was measured

The main endpoint, also called the primary outcome, was the immune response enhanced or induced by autologous tumor lysate-loaded XP-DC in epithelial ovarian cancer patients.[1] A primary outcome is the main result the researchers plan to measure.[1]

The brief summary says the main objective was to show immunological efficacy of tumor-lysate loaded XP-DC in patients undergoing chemotherapy.[1] Immunological efficacy means the treatment was being tested for its ability to create a useful immune effect in the body.[1]

Key trial details

Item Information from the trial
Trial ID NCT05773859[1]
Title Induction of neo-antigen specific T cells by specialized cross-presenting dendritic cells in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy, the NEODOC study[1]
Status Completed[1]
Phase Phase 1/2[1]
Condition Ovarian cancer[1]
Enrollment 10 participants[1]
Intervention XP-DC+TL+KLH given intranodally[1]
Main outcome Immune response / immunological efficacy[1]

What the trial means for patients

This trial was small and early, so it was mainly designed to learn whether the treatment can trigger an immune response in a specific group of ovarian cancer patients.[1] It did not study a broad population, but instead focused on patients already receiving chemotherapy around the time of surgery or main treatment.[1]

Because the study was completed and only 10 people were enrolled, the data are best seen as early research evidence rather than a final answer about treatment benefit.[1]

Trial ID Phase Condition studied Status Enrollment
NCT05773859 Phase 1/2 Epithelial ovarian cancer Completed 10

FAQ

  • What is being studied in the Xp-Dc+Tl+Klh trials? The trial is studying whether Xp-Dc+Tl+Klh can help create a stronger immune response in epithelial ovarian cancer. The main goal is to see if it can support the body’s defense against the tumor.
  • Who can take part in these trials? The trial includes patients with epithelial ovarian cancer. It focuses on women receiving neoadjuvant or adjuvant chemotherapy, which means chemotherapy given before or after the main cancer treatment.
  • What phase is the Xp-Dc+Tl+Klh trial? The study is a Phase 1/2 trial. Phase 1/2 studies usually look at early signs of safety and whether the treatment shows biological or clinical activity.
  • What outcome is the trial measuring? The main outcome is immune response. The study checks whether autologous tumor lysate-loaded XP-DC can enhance or induce immunity in patients with epithelial ovarian cancer.
  • How many people were enrolled? This trial enrolled 10 participants. It was a small study, which is common in early-phase clinical research.

Ongoing Clinical Trials on Xp-Dc+Tl+Klh

  • Study on the Effects of XP-DC+TL+KLH in Patients with Ovarian Cancer Undergoing Chemotherapy

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

Glossary

  • Clinical trial: A research study in people that tests whether a treatment is safe, works, or both.
  • Interventional study: A study where researchers give a treatment or procedure and then measure the results.
  • Phase 1/2: An early stage of testing that looks at safety, early activity, and signs that the treatment may help.
  • Epithelial ovarian cancer: A type of ovarian cancer that starts in the cells covering the ovary.
  • Neoadjuvant chemotherapy: Chemotherapy given before the main treatment, often to shrink the cancer first.
  • Adjuvant chemotherapy: Chemotherapy given after the main treatment to help lower the chance that cancer returns.
  • Immune response: The body’s defense reaction against harmful cells or germs.
  • Autologous: Made from the same person’s own cells or tissue.
  • Tumor lysate: A mixture made from broken-down tumor cells, used in some research studies to help train the immune system.
  • Primary endpoint: The main result a study is designed to measure.

References